Aktis Oncology Q1 FY26 net loss widens to $18.3 million; revenue climbs to $3.2 million

• Aktis Oncology posted a net loss of $18.3 million for first-quarter 2026, widening from a $15 million loss a year earlier.
• Collaboration revenue rose to $3.2 million from $1.4 million, on continued advancement of its research collaboration with Eli Lilly.
• R&D expenses climbed to $20 million from $15.9 million, while G&A costs increased to $5.9 million from $3.7 million.
• Cash, cash equivalents and marketable securities totaled $538.5 million at March 31, up from $226.8 million at year-end 2025, following gross IPO proceeds of about $365.4 million; cash runway expected into 2029.
• Initiated a Phase 1b trial of AKY-2519 in metastatic castration-resistant prostate cancer with preliminary data expected in 2027; plans to start a Phase 1b basket trial in other B7-H3 solid tumors in second-half 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-216716), on May 11, 2026, and is solely responsible for the information contained therein.